RP & dry AMD candidate on the fast track

Article

Neurotech Pharmaceuticals has been granted Fast Track designations by the FDA for NT-501 for the treatment of visual loss in retinitis pigmentosa (RP) and dry age-related macular degeneration (AMD).

Neurotech Pharmaceuticals has been granted Fast Track designations by the FDA for NT-501 for the treatment of visual loss in retinitis pigmentosa (RP) and dry age-related macular degeneration (AMD).

NT-501 is an intraocular, cell-containing polymer implant that has been developed to provide continuous, long-term release of the therapeutic protein Ciliary Neurotrophic Factor (CNTF) directly into the back of the eye via the company's proprietary Encapsulated Cell Technology.

Neurotech is currently conducting two Phase II/III trials of NT-501 for the treatment of visual loss associated with RP in both its earlier and later stages. It is also carrying out a Phase II study evaluating NT-501 in 48 patients with dry AMD.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.